Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma

Collin K. Chin, Loretta J. Nastoupil

Research output: Contribution to journalReview articlepeer-review

Abstract

Follicular lymphoma is the most common indolent non-Hodgkin lymphoma. Although median overall survival rates exceed 12 years with rituximab, follicular lymphoma remains largely incurable. The growing understanding of the molecular drivers of lymphomagenesis and the tumor microenvironment have led to novel therapies. Prognostic markers have identified a subset of patients with chemoresistant and/or refractory disease-associated poor outcomes. We identify the patients with follicular lymphoma in need of novel therapies, describe the drivers of lymphomagenesis and importance of the tumor microenvironment, and summarize the novel agents under investigation in relapsed/refractory and upfront follicular lymphoma.

Original languageEnglish (US)
Pages (from-to)743-756
Number of pages14
JournalHematology/Oncology Clinics of North America
Volume34
Issue number4
DOIs
StatePublished - Aug 2020

Keywords

  • Antibody-drug conjugates
  • BCL2 inhibitors
  • Bispecific antibodies
  • Checkpoint inhibitors
  • Epigenetic therapies
  • Follicular lymphoma
  • Novel agents
  • POD24

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma'. Together they form a unique fingerprint.

Cite this